Navigation Links
Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
Date:10/6/2010

SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California. Lorcaserin, which Arena discovered and developed, is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

"Obesity 2010 is an excellent scientific forum to present results from our recently completed clinical study evaluating the effects of lorcaserin on appetite, energy intake and energy expenditure," stated William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "We look forward to presenting at this event, and to lorcaserin's October 22nd PDUFA date."

The meeting schedule includes presentations of a lorcaserin mechanism of action study conducted by Drs. Eric Ravussin, Leanne Redman, Corby Martin and Steven Smith at the Pennington Biomedical Research Center in Baton Rouge, Louisiana.

Saturday, October 9, 2010

  • Oral Abstract Presentation: Lorcaserin, a Novel 5-HT2C Receptor Agonist, Causes Weight Loss Without Stimulating Energy Expenditure
  • Session Time:  4:45 p.m. - 6:15 p.m. Pacific Time (PT)

  • Sunday, October 10, 2010

  • Poster Presentation: Lorcaserin, a Selective 5-HT2C Receptor Agonist, Reduces Energy Intake and Appetite
  • Session Time: The poster will be on display from 9:30 a.m. to 1:45 p.m. PT and from 3:15 p.m. to 6:30 p.m. PT. Presenters will be available to discuss the poster from 12:30 p.m. to 1:30 p.m. PT.

  • About LorcaserinLorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

    About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management and has completed a pivotal Phase 3 clinical trial program. Arena has filed an NDA for lorcaserin with the FDA, and the FDA has assigned a PDUFA date of October 22, 2010, for review of the application. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States.

    Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

    About Eisai Inc.Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2009 (year ended March 31, 2010) sales of approximately $3.9 billion. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd.

    Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.

    Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and regulatory review and approval of lorcaserin; how lorcaserin is believed to act; lorcaserin's patent coverage; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the risk that regulatory authorities may not find data from Arena's clinical trials and other studies sufficient for regulatory approval; the timing of any regulatory review and approval is uncertain; Arena's ability to obtain and defend its patents; risks related to commercializing new products; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; the timing and receipt of payments and fees, if any, from Eisai and Arena's collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contacts: Arena Pharmaceuticals, Inc.Investor Inquiries:

    Media Inquiries: Russo PartnersCindy McGee

    David Schullcmcgee@arenapharm.com

    david.schull@russopartnersllc.com858.453.7200, ext. 1479

    858.717.2310Contacts: Eisai Inc. Investor Inquiries:

    Media Inquiries: Dave Melin

    Lynn Kenneydavid_melin@eisai.com

    lynn_kenney@eisai.com908.255.6378

    201.746.2294
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
    2. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
    3. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
    4. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
    5. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
    6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
    7. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    8. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
    9. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
    10. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
    11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
    (Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
    (Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
    Breaking Medicine Technology:
    (Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
    (Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
    (Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
    (Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
    Breaking Medicine News(10 mins):